Health Professional Radio - Podcast

Dr. James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurrent C. difficile (rCDI) infection. The current standard of care treatment for rCDI is currently antibiotics. While they are important, they do not restore the underlying health of the gut microbiome, nor can they stop C. diff​icile​ spores from growing back. He talks about what their late stage pivotal Phase 3 clinical trial results showed regarding mitigating recurrent C. difficile infection.​ ​The ​gut ​microbiome is an emerging area where biotherapeutics are being developed to address certain diseases and conditions.​ #FerringPharmaceuticals #ClostridioidesDifficileInfection Dr. James Tursi is responsible for U.S. Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance (PV), Project Planning and Regulatory Affairs. James collectively has over 30 years of experience in medicine and nearly 20 years in the pharmaceutical indust